Rinvecalinase Alfa Pharmacokinetic Studies Market

Phase I accounts for 45.7% of the rinvecalinase alfa pharmacokinetic studies market by study phase. Preeclampsia leads the indication category with 43.2%, while single ascending dose studies hold 44.9% of the study type segment.